
share finish today follow releas
result think investor emphat sent signal manag
board chang need occur clearli stock drop
magnitud could possibl tie revenu miss think
larger issu weigh share includ lack clariti
result board strateg review announc
need signific ramp revenu profit order
co achiev financi target view investor
patienc basic run still think myl new gener
product includ wixela inhub gener gsk advair recent
launch biosimilar like fulphia us like continu gain
traction market share us manag indic
new product revenu gener heavi capit
invest co make support launch near-
term neg impact cash flow manag reiter
comfort level financi guidanc strong second half
perform requir attain target remain buy rate
share pt
market cap eras follow today share plummet
investor clearli happi whether tie poor execut
lack transpar think myl board need address
situat hand come action plan
restor investor confid myl busi think result
improv come quarter manag team need
better job commun front
think major reason share new low
poor execut part manag co host
investor day later summer earli fall may help believ
co need focu better execut quarter focu
set expect meet exceed
valuat arriv pt appli multipl
estim discount back
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
morn report revenu vs estimate adj ep vs estimate
revenu forecast co gross margin bp higher estim
manag reiter comfort level financi guidanc includ revenu
adj ep adj strong second half perform requir attain
target lower revenu estimate ep forecast
ebitda estimate remain intact
revenu miss forecast bulk shortfal come european
segment declin yoy tie neg fx currenc headwind manag
morn call also cite temporari busi disrupt due serial across europ
neg impact quarterli revenu american segment revenu declin yoy even sale
new product co gener sale new product global
guidancebtig estimatesbtig revenu gross total sg total net adj adj free effect tax dilut share co report btig estimatesfinanci guidanc btig estimatesmylan incom statement lower north cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut analysissal co report btig estim
wixela inhub launch gain traction us co made signific capit invest
late januari fda approv myl gener version advair fluticasone/salmeterol treatment
asthma/copd estim brand market opportun us view approv gener
version advair import mileston co first-to-market opportun could still gener
signific revenu even though glaxosmithklin gsk rate advair sale declin
still meaning sale opportun brand sale still excess us
accord symphoni health advair high unit volum product total monthli prescript
estim gener advair sale could conserv figur
myl gener version advair wixela inhub includ three strength mcg mcg
mcg asthma patient sold discount brand counterpart advair disku
less gsk author gener version accord symphoni health product garner
share total volum sinc launch februari
mylan biosimilar pipelin includ dozen product
believ dozen biosimilar product opportun includ top best-sel
biolog product believ could posit launch biosimilar version herceptin
trastuzumab brand market opportun us current partner biocon bio
rate biosimilar includ fulphila biosimilar rate neulasta pegfilgrastim
launch last year continu steadili gain share inject market uptak biosimilar
us slow past year think could begin chang increas scrutini
high price brand biolog occur
major biolog product target includ lantu avastin humira humalog
enbrel last octob launch hulio biosimilar rate humira europ
partner fujifilm kyowa kirin biolog rate european market becom
competit switch biosimilar move rapidli within mani european countri unlik us patent
major biolog expir includ enbrel remicad humira
partner biocon biosimilar includ lantu avastin humira humalog
enbrel last octob launch hulio biosimilar rate humira europ
 incom statement financi project cost sg adj oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut co report btig
btig cover compani mention report
appendix analyst certif import disclosur
